Bryologyx
Dr. Vidal brings to Bryologyx more than 17 years’ experience in pharmaceutical product development, with expertise in API development and manufacturing from pilot through commercial scale, and in working with contract manufacturing organizations. He has served at companies including Celgene, Codexis, and Hospira. He holds a PhD in Chemistry from Stony Brook University.
This person is not in any offices
Bryologyx
BryoLogyx is developing a new class of drugs to enhance the response rates and treatment durability of cancer immunotherapies.